Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 129

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 2
Chunk 129
---
 of the voluntary recall of certain enVista IOL products.Selling, General and Administrative ExpensesSG&A expenses were $1,142 million and $1,039 million for the six months ended June 30, 2025 and 2024, respectively, an increase of $103 million, or 10%. The increase was primarily attributable to: (i) higher selling and advertising and promotion costs, primarily attributable to MIEBO® and (ii) higher Business Transformation Costs (defined and discussed below).Research and Development ExpensesR&D expenses were $182 million and $166 million for the six months ended June 30, 2025 and 2024, respectively, an increase of $16 million, or 10%, primarily due to certain products in development, as previously discussed.Amortization of Intangible AssetsAmortization of Intangible assets was $134 million and $148 million for the six months ended June 30, 2025 and 2024, respectively, a decrease of $14 million, or 9%, primarily due to fully amortized intangible assets no longer being amortized.

45

See Note 8, “INTANGIBLE ASSETS AND GOODWILL” to our unaudited interim Condensed Consolidated Financial Statements for further details related to the Amortization of intangible assets.Other expense, netOther expense, net for the six months ended June 30, 2025 and 2024 consists of the following:Six Months EndedJune 30,(in millions)20252024Asset impairments$— $5 Restructuring, integration and separation costs32 17 Gain on sale of assets— (5)Litigation and other matters7 1 Acquired in-process research and development costs29 3 Acquisition-related costs3 1 Acquisition-related contingent consideration(27)1 Other expense, net$44 $23 Acquired in-process research and development costs in 2025 primarily relate to the acquisition of Whitecap Biosciences, as previously discussed.Operating (Loss) IncomeOperating loss was $94 million for the six months ended June 30, 2025, as compared to operating income of $32 million for the six months ended June 30, 2024, a decrease in our operating results of $126 million. This decrease primarily reflects the increase in SG&A and other expense, each as previously discussed.Segment ProfitThe following table presents segment profits, segment profits as a percentage of segment revenues and